Market Overview:

The Global Angina Pectoris Drugs Market size was valued at USD 11.61 Billion in 2023 and is projected to grow at a CAGR of 4.3% from 2024 to 2032.

The rising frequency of cardiovascular illnesses all over the planet is one of the elements moving the worldwide market for angina pectoris drugs. Since cardiovascular illnesses rank among the main sources of death around the world, there is a more prominent requirement for proficient treatments. Transdermal fixes and supported discharge details are two instances of novel medication conveyance innovations that are working on the viability and consistence of drugs for angina pectoris.

The market is significantly affected by the growing geriatric populace, which likewise raises the gamble of cardiovascular illnesses in older people. Drug organizations presently get the opportunity to give customized medicines that meet the exceptional necessities of senior people and improve their personal satisfaction because of this segment change. Drug organizations' essential associations and joint efforts with scholastic foundations are likewise impelling the market's development by speeding up the medication revelation process and advancing the production of creative medication details.

Enhancements in cardiology care, progressing innovative work, and an ascent in the quantity of restorative endorsements from administrative bodies, for example, the FDA are likewise driving business sector open doors. Because of the developing number of retail drug stores and patients' penchant to purchase angina drugs from these chains, new business sectors are arising. Drug organizations can make and offer new meds to address the developing interest for angina pectoris treatments welcomed on by the maturing of the worldwide populace.

Key Findings:

• Ischemic coronary illness stays the main source of worldwide CVD mortality with an age-normalized rate per 100,000 of 108.8 passing, trailed by intracerebral drain and ischemic stroke.
• High systolic circulatory strain represented the biggest commitment to inferable age-normalized CVD incapacity changed life years (DALYs) at 2,564.9 per 100,000 around the world.
• Dietary dangers were the main supporter old enough normalized CVD DALYs among the conduct chances, while surrounding particulate matter contamination drove the natural dangers.
• Between 2015-2022, age-normalized CVD mortality expanded in 27 out of 204 areas.
• Worldwide demise counts because of CVD expanded from 12.4 million of every 1990 to 19.8 million out of 2022 reflecting worldwide populace development and maturing and the commitments from preventable metabolic, natural, and conduct gambles.
• Eastern Europe had the most noteworthy age-normalized absolute CVD mortality at 553 passing for every 100,000. Conversely, nations in Australasia had the least age-normalized absolute CVD mortality at 122.5 passing per 100,000 individuals.
• Focal Asia, Eastern Europe, North Africa and the Centre East had the most noteworthy age-normalized death rate per 100,000 individuals inferable from high systolic circulatory strain. The locales with the most noteworthy paces of CVD trouble inferable from dietary gamble were Focal Asia, Oceania, and portions of North Africa and the Centre East.

Market Dynamics - Market Drivers

Increasing Prevalence of Cardiovascular Diseases

One of the essential drivers for the worldwide angina pectoris drugs market is the rising occurrence of cardiovascular sicknesses (CVDs) around the world. Stationary ways of life, unfortunate weight control plans, and elevated degrees of stress have prompted an expansion in heart-related conditions, with angina pectoris being a typical side effect of coronary conduit illness (computer aided design). As the populace ages, the vulnerability to heart conditions likewise develops, which fills the interest for viable angina pectoris prescriptions. As indicated by the World Wellbeing Association, CVDs are the main source of death universally, building up the requirement for cutting edge medicines, including drug treatments.

Technological Advancements in Drug Development

The market is likewise determined by continuous advancements in drug innovative work. New medication conveyance frameworks, upgraded details, and customized medication approaches are making more compelling and designated medicines for angina pectoris. This incorporates the advancement of novel medication classes like calcium channel blockers, beta-blockers, and nitrates, which offer huge upgrades in side effect the executives and patient results. These mechanical headways are decreasing secondary effects and expanding patient consistence, further impelling business sector development.

Market Opportunities

Growing Focus on Preventive Healthcare

The shift toward preventive medical services presents huge learning experiences for the angina pectoris drugs market. Expanding mindfulness about heart wellbeing and the significance of early determination has prompted more popularity for drugs that oversee angina as well as forestall its movement. This pattern is supposed to speed up, especially in developing business sectors, where medical care frameworks are improving and populaces are turning out to be more wellbeing cognizant.

Expansion into Emerging Markets

Arising economies, especially in Asia-Pacific and Latin America, offer extensive open doors for market development. These districts are seeing an ascent in cardiovascular sickness cases because of urbanization, evolving ways of life, and further developed medical services framework. Besides, legislatures and confidential medical care suppliers are putting resources into extending admittance to medical services, which incorporates therapies for heart conditions like angina pectoris. Drug organizations can take advantage of these developing business sectors by offering reasonable, available medication choices.

Market Restraining Factors

High Cost of Treatment

High cost remains the most significant restraint to market growth, particularly the newer formulations for angina pectoris. Advanced therapies are invariably expensive and therefore unreachable in low- and middle-income countries. Similarly, even in developed markets, expensive long-term treatment becomes unaffordable for some patients and results in them not adhering to the prescribed medication regimens. This cost barrier restricts overall market potential and underscores the need for cost-effective drug solutions.

Side Effects and Drug Resistance

Another challenge to the angina pectoris drugs market is side effects from which they are likely to suffer, as well as drug resistance in patients. Effects such as headaches, dizziness, and the feeling of fatigue may de-motivate patients from further continuation of their medicine, thus creating a poor outcome of treatment. Moreover, long-term use of some drugs can lead to reduced efficacy, hence calling for alternative medication treatments. This poses a significant challenge to drug-making companies and highlights the need for further research into these matters.

Key Findings:

Modifiable risk factors that contributed to CVD deaths in 2021 include:

• Elevated LDL cholesterol (3.8 million deaths)
• High fasting plasma glucose (2.3 million deaths)
• Air pollution (4.8 million deaths)
• High body-mass index (2.0 million deaths)
• Tobacco use (3.0 million deaths)
• Low physical activity (397 000 deaths)
• Raised blood pressure (10.8 million deaths).

Segmentation Analysis

The market scope is segmented because of by Drug Class, by Type, by Application.

By Drug Class

Based on the Drug Class of the market is segmented into Nitrates, Beta Blockers, Anticoagulants, Anti-Platelets, Calcium Antagonists, Other Drug Classes.

In 2023, beta blockers constituted a 39.2% market share of angina pectoris sales, thus leading the segment. Its increased adoption as a first-line treatment for angina pectoris is one of the key factors driving the segment forward. The growing elderly population and firm-level strategic market moves to increase commercial availability of beta blockers also contribute to this growth factor. These agents are a critical medication option for an aging population due to their effect on reducing heart rate and depressing cardiac muscle contractions.

The projection period will see the anticoagulants market grow at a notable rate. Since most anticoagulant drugs are administered to patients with angina pectoris in a bid to avert blood clots and the subsequent cardiovascular results, the higher number of cases reported for this disease calls for the growth in the market. New oral anticoagulants have revolutionized the market by making safer and more efficient substitutes of traditional warfarin, and this has really paved the way for expansion.

By Type

Based on the Type of the market is segmented into Stable Angina, Unstable Angina, Prinz metal Angina, Micro vascular Angina.

Stable angina accounted for 51.8% in revenue in 2023, accounting for the largest share of the angina pectoris medication market. Chronic stable angina is becoming more common, and in approximately half of these, it is the first symptom of ischemic heart disease. Stable angina can also be triggered by variables such as cold weather or physical activity, explaining why this particular market is on the upswing. There are numerous reasons for the stable angina segment's dominance, including public awareness, research and development, and efficient treatment alternatives.

During the forecast period, the unstable angina category will increase at the fastest rate, 5.8%. A key contributing cause to the increasing incidence of cardiovascular diseases (CVDs) is the aging population, along with lifestyle choices such as smoking, poor diets, and lack of exercise. With the increased CVD patient population, the demand for angina pectoris drugs also increased, especially the unstable angina, a more severe form of the disease. The recent improvement in healthcare infrastructure, advanced diagnostic technology and the rising awareness of CVDs have been able to identify unstable angina earlier. Early detection and treatment promote market growth.

Regional Snapshots

By region, Insights into the markets in North America, Europe, Asia-Pacific, Latin America and MEA are provided by the study. North America dominates the angina pectoris drugs market in large part due to the region's well-established healthcare system, increased therapeutic use, and the presence of significant American manufacturers. Angina is the most common manifestation of ischemic heart disease-the number one cause of death and disability in North America. For instance, data published in February 2022 by the Division for Heart Disease and Stroke Prevention of the National Centre for Chronic Disease Prevention and Health Promotion show that ischemic heart disease, the most common heart disease, was responsible for 360,900 deaths in 2019. Approximately 18.2 million people above age 20 have coronary artery disease. About two out of ten deaths due to coronary heart disease occur in people under 65 years of age.

Similarly, an article titled "Ischemic Heart Disease: Non-invasive Imaging Techniques and Findings" published in RSNA (Radiographic) in May 2021 reported that the prevalence of ischemic heart disease currently stands at approximately 18.2 million cases, with an annual incidence of new coronary events about 720,000 cases only in the United States. With the growing rate of heart diseases due to which the incidence of angina pectoris is on the rise, the area would witness a probable increase in demand for angina pectoris medications. The clinical trials are also proliferating and hence the market. For instance, in the United States, there were 23 on-going or recruiting clinical studies involving angina pectoris till April of 2022. Consequently, during this study period, these factors altogether promote the growth of the angina pectoris medication market.

List of Companies Profiled

• Bayer AG
• Amgen Inc.
• Pfizer Inc.
• AstraZeneca
• Novartis AG
• Gilead Sciences
• GlaxoSmithKline Plc.
• Merck & Co., Inc.
• Eli Lilly and Company
• Otsuka Pharmaceutical Co., Ltd.
• Sanofi S.A.
• Boehringer Ingelheim International GmbH

Key Industry Developments

In May 2024, Novartis and AC Health entered a partnership for integrated cardiovascular and cancer care, with the objective of expanding access to innovative medicines in the areas of cancer, cholesterol, and heart failure, as well as empowering patients through this collaborative effort.

In July 2023, Riparian Pharmaceuticals partnered with Pfizer to advance novel cardiovascular programs, granting Pfizer exclusive rights to a preclinical program to support Riparian’s efforts to discover further drug targets for vasoprotection.

Report Coverage

The report will cover the qualitative and quantitative data on the global Angina Pectoris Drugs Market. The qualitative data includes latest trends, market players analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

Report Scope and Segmentations

Regional Analysis

North America accounted for the highest xx% market share in terms of revenue in the Angina Pectoris Drugs market and is expected to expand at a CAGR of xx% during the forecast period. This growth can be attributed to the growing adoption of Angina Pectoris Drugs. The market in APAC is expected to witness significant growth and is expected to register a CAGR of xx% over upcoming years, because of the presence of key Angina Pectoris Drugs companies in economies such as Japan and China.

The objective of the report is to present comprehensive analysis of Global Angina Pectoris Drugs Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.

Angina Pectoris Drugs Market Report is also available for below Regions and Country Please Ask for that

North America

• U.S
• Canada

Europe

• Switzerland
• Belgium
• Germany
• France
• U.K
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Rest of Europe

Asia-Pacific

• India
• Australia
• Philippines
• Singapore
• South Korea
• Japan
• China
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Argentina
• Peru
• Colombia
• Brazil
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Points Covered in the Report

• The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
• The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 5 years data history and forecast.
• The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
• Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.
• The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Questions

• How much the global Angina Pectoris Drugs Market valued?
• Which region has the largest share in 2024 for the global Angina Pectoris Drugs Market?
• What are the driving factors for the market?
• Which is the leading segment in the global market?
• What are the major players in the market?

Research Scope of the Market

• Historic year: 2019-2022
• Base year: 2023
• Forecast: 2024 to 2032
• Representation of Market revenue in USD Million

Angina Pectoris Drugs Market Trends: Market key trends which include Increased Competition and Continuous Innovations Trends: